Different intestinal permeability patterns in relatives and spouses of patients with Crohn's disease: An inherited defect in mucosal defence?

Gut

Volumn 44, Issue 1, 1999, Pages 96-100

  Soderholm J D ^a   Olaison, G ^a   Lindberg, E ^b   Hannestad, U ^c   Vindels, A ^a   Tysk, C ^c   Jarnerot G ^c   Sjodahl R ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

^c NONE

Author keywords

Acetylsalicylic acid; Environmental; Genetics; Inflammatory bowel disease; Lactulose; Mannitol

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID; LACTULOSE; MAGNECYL; MANNITOL; MESALAZINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; FEMALE; GENETIC DISORDER; HOST RESISTANCE; HUMAN; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RELATIVE; SPOUSE; URINARY EXCRETION;

EID: 0033003669     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.44.1.96     Document Type: Article

References (39)

1. 1 Olaison G, Sjödahl R, Tagesson C. Abnormal intestinal permeability in Crohn's disease. A possible pathogenic factor. Scand J Gastroenterol 1990;25:321-8.
2. 2 Hollander D. The intestinal permeability barrier. A hypothesis to its regulation and involvement in Crohn's disease. Scand J Gastroenterol 1992;27:721-6.
3. 3 Travis S, Menzies T. Intestinal permeability: functional assessment and significance. Clin Sci 1992;82:471-88.
4. 4 Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology 1995;108:1566-81.
5. 5 Madara JL, Parkos C, Colgan S, et al. The movement of solutes and cells across tight junctions. Ann NY Acad Sci 1992;664:47-60.
6. 6 Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-Cadherin. Science 1995;270:1203-7.
7. 7 Sachar DB. Crohn's disease: a family affair. Gastroenterology 1996;111:813-15.
8. 8 Tysk C, Lindberg H, Järnerot G, et al. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dixygotic twins. A study of heritability and the influence of smoking. Gut 1988;29:990-6.
9. 9 Satsangi J, Jewell DP, Bell JI. The genetics of inflammatory bowel disease. Gut 1997;40:572-4.
10. 10 Hollander D, Vadheim CM, Brettholz E, et al. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med 1986;105:883-5.
11. 11 Teahon K, Smethurst P, Levi AJ, et al. Intestinal permeability in patients with Crohn's disease and their first degreee relatives. Gut 1992;33:320-3.
12. 12 Ruttenberg D, Young GO, Wright JP, et al. PEG 400 excretion in patients with Crohn's disease, their first degree relatives, and healthy volunteers. Dig Dis Sci 1992;37:705-8.
13. 13 Lindberg E, Söderholm JD, Olaison G, et al. Intestinal permeability to polyethylene glycols in monozygotic twins with Crohn's disease. Scand J Gastroenterol 1995;30:780-3.
14. 14 Hollander D. Permeability in Crohn's disease: altered barrier functions in healthy relatives? Gastroenterology 1993;104:1848-51.
15. 15 Ainsworth M, Eriksen J, Rasmussen JW, et al. Intestinal permeability of 51 Cr-labelled ethylenediaminetetraacetic acid in patients with Crohn's disease and their first degree relatives. Scand J Gastroenterol 1989;24:993-8.
16. 16 Munkholm P, Langholz E, Hollander D, et al. Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives. Gut 1994;35:68-72.
17. 17 May G, Sutherland L, Meddings J. Is small intestinal permeability really increased in relatives of patients with Crohn's disease? Gastroenterology 1993;104:1627-32.
18. 18 Yacyshyn BR, Meddings JB. CD45RO expression on circulating CD19+ B-cells in Crohn's disease correlates with intestinal permeability. Gastroenterology 1995;108:132-7.
19. 19 Hilsden RJ, Meddings JB, Sutherland LR. Intestinal permeability changes in response to acetylic salicylic acid in relatives of patients with Crohn's disease. Gastroenterology 1996;110:1395-403.
20. 20 Pironi L, Miglioli M, Ruggeri E, et al. Effect of non-steroidal anti-inflammatory drugs on intestinal permeability in first degree relatives of patients with Crohn's disease. [Abstract] Gastroenterology 1992;102:A679.
21. 21 Peeters M, Geypens B, Claus D, et al. Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology 1997;113:802-7.
22. 22 Pera A, Bellando P, Caldera D, et al. Colonoscopy in inflammatory bowel disease. Diagnostic accuracy and proposal of an endoscopic score. Gastroenterology 1987;92:181-5.
23. 23 Morson BC. Histopathology of Crohn's disease. Proc R Soc Med 1968;61:79-81.
24. 24 Best WR, Becktel JM. The Crohn's disease activity index as a clinical instrument. In: Pena A, Weterman IT, Booth CC, et al, eds. Recent advances in Crohn's disease. The Hague: Martinus Nijhoff, 1981:7-12.
25. 25 Kynaston JA, Fleming SC, Laker MF, et al. Simultaneous quantification of mannitol, 3-O-methyl glucose, and lactulose in urine by HPLC with pulsed electrochemical detection, for use in studies of intestinal permeability. Clin Chem 1993;39:453-6.
26. 26 Russel MGVM, Stockbrügger RW. Epidemiology of inflammatory bowel disease: an update. Scand J Gastroenterol 1996;31:417-27.
27. 27 Brodie DA, Tatae CL, Hooke KF. Aspirin: intestinal damage in rats. Science 1970;170:183-5.
28. 28 Davies NM, Corrigan BW, Jamali F. Sucrose urinary excretion in the rat measured using a simple assay: a model for gastroduodenal permeability. Pharmacol Res 1995;12: 1733-6.
29. 20 Meddings JB, Sutherland LR, Byles NI, et al. Sucrose: a novel permeability marker for gastroduodenal disease. Gastroenterology 1993;104:1619-26.
30. 30 Bjarnason I, Batt R, Catt S, et al. Evaluation of differential disaccharide excretion in urine for non-invasive investigation of altered intestinal disaccharidase activity caused by a-glucosidase inhibition, primary hypolactasia, and coeliac disease. Gut 1996;39:374-81.
31. 51 Gatti G, Barzaghi N, Attardo Parinello G, et al. Pharmacokinetics of salicylic acid following administration of aspirin tablets and three different forms of soluble aspirin in normal subjects. International Journal of Pharmacological Research 1989;9:385-9.
32. 32 Muir N, Nichols JD, Clifford JM, et al. The influence of dosage form on aspirin kinetics: implications for acute cardiovascular use. Curr Med Res Opin 1997;13:547-53.
33. 33 Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997;112:1000-16.
34. 34 Ahrensted Ö, Knutson L, Nilsson B, et al. Enhanced local production of complement components in the small intestines of patients with Crohn's disease. N Engl J Med 1990; 322:1345-9.
35. 35 Marteau P, Colombel JF, Nemeth J, et al. Immunological study of histologically non-involved jejunum in Crohn's disease: evidence for reduced in vivo secretion of secretory IgA. Clin Exp Immunol 1990;80:196-201.
36. 36 Olaison G, Sjödahl R, Tagesson C. Decreased gastrointestinal absorption of peroral polyethylene glycols (PEG 1000) in Crohn's disease. A sign of jejunal abnormality. Acta Chirurgica Scandinavica 1987;153:373-7.
37. 37 Peeters M, Ghoos Y, Maes B, et al. Increased permeability of macroscopically normal small bowel in Crohn's disease. Dig Dis Sci 1994;39:2170-6.
38. 38 Somasundaram S, Rafi S, Hayllar J, et al. Mitochondrial damage: a possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine. Gut 1997;41: 344-53.
39. 39 Somasundaram S, Hayllar H, Rafi S, et al. The biochemical basis of non-steroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: a review and a hypothesis. Scand J Gastroenterol 1995;30:289-99.